Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells

Molecular Carcinogenesis

Volumn 52, Issue 3, 2013, Pages 218-228

  Wang, Xiaoqi ^a   Li, Guangyuan ^a   Wang, Antai ^a   Zhang, Zhenfeng ^a   Merchan, Jaime R ^b   Halmos, Balazs ^a  

^a Department of Medicine   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Angiogenesis; COXs; HDAC inhibitor; Lung cancer; PGE2

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; HISTONE DEACETYLASE INHIBITOR; INDOMETACIN; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; TRICHOSTATIN A; VORINOSTAT;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME REACTIVATION; LUNG CANCER; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; UPREGULATION;

ANGIOGENESIS INHIBITORS; CELL LINE, TUMOR; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DRUG SYNERGISM; EPITHELIAL CELLS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; INDOMETHACIN; LUNG NEOPLASMS; PYRAZOLES; SULFONAMIDES;

EID: 84873261115     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21846     Document Type: Article

References (29)

1. Holla VR, Backlund MG, Yang P, Newman RA, DuBois RN. Regulation of prostaglandin transporters in colorectal neoplasia. Cancer Prev Res (PhilaPa) 2008; 1: 93- 99.
2. Tai HH, Cho H, Tong M, Ding Y. NAD+-linked 15-hydroxyprostaglandin dehydrogenase: Structure and biological functions. Curr Pharm Des 2006; 12: 955- 962.
3. Anggard E, Larsson C, Samuelsson B. The distribution of 15-hydroxy prostaglandin dehydrogenase and prostaglandin-delta 13-reductase in tissues of the swine. Acta Physiol Scand 1971; 81: 396- 404.
4. Moreno J, Krishnan AV, Swami S, Nonn L, Peehl DM, Feldman D. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res 2005; 65: 7917- 7925.
5. Myung SJ, Rerko RM, Yan M, et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci USA 2006; 103: 12098- 12102.
6. Wolf I, O'Kelly J, Rubinek T, et al. 15-Hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res 2006; 66: 7818- 7823.
7. Backlund MG, Mann JR, Holla VR, et al. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem 2005; 280: 3217- 3223.
8. Huang G, Eisenberg R, Yan M, et al. 15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancer. Cancer Res 2008; 68: 5040- 5048.
9. Richon VM, Emiliani S, Verdin E, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 1998; 95: 3003- 3007.
10. Richon VM, Garcia-Vargas J, Hardwick JS. Development of vorinostat: Current applications and future perspectives for cancer therapy. Cancer Lett 2009; 280: 201- 210.
11. Kim MS, Kwon HJ, Lee YM, et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001; 7: 437- 443.
12. Deroanne CF, Bonjean K, Servotte S, et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 2002; 21: 427- 436.
13. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007; 12: 1247- 1252.
14. Paik PK, Krug LM. Histone deacetylase inhibitors in malignant pleural mesothelioma: Preclinical rationale and clinical trials. J Thorac Oncol 2010; 5: 275- 279.
15. Traynor AM, Dubey S, Eickhoff JC, et al. Vorinostat (NSC #701852) in patients with relapsed non-small cell lung cancer: A Wisconsin Oncology Network Phase II Study. J Thorac Oncol 2009; 4: 522- 526.
16. Pitts TM, Morrow M, Kaufman SA, Tentler JJ, Eckhardt SG. Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models. Mol Cancer Ther 2009; 8: 342- 349.
17. Ramalingam SS, Maitland ML, Frankel P, et al. Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 56- 62.
18. Merchan JR, Chan B, Kale S, Schnipper LE, Sukhatme VP. In vitro and in vivo induction of antiangiogenic activity by plasminogen activators and captopril. J Natl Cancer Inst 2003; 95: 388- 399.
19. Merchan JR, Jayaram DR, Supko JG, He X, Bubley GJ, Sukhatme VP. Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: Potentiation by Cox-2 inhibition. Int J Cancer 2005; 113: 490- 498.
20. Sanchez-Alcazar JA, Bradbury DA, Pang L, Knox AJ. Cyclooxygenase (COX) inhibitors induce apoptosis in non-small cell lung cancer through cyclooxygenase independent pathways. Lung Cancer 2003; 40: 33- 44.
21. Profita M, Sala A, Bonanno A, et al. Chronic obstructive pulmonary disease and neutrophil infiltration: Role of cigarette smoke and cyclooxygenase products. Am J Physiol Lung Cell Mol Physiol 298: L261- L269.
22. Chen Y, Chen P, Hanaoka M, Droma Y, Kubo K. Enhanced levels of prostaglandin E2 and matrix metalloproteinase-2 correlate with the severity of airflow limitation in stable COPD. Respirology 2008; 13: 1014- 1021.
23. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005; 352: 1967- 1976.
24. Herschman HR. Prostaglandin synthase 2. Biochim Biophys Acta 1996; 1299: 125- 140.
25. Fort J. Celecoxib, a COX-2-specific inhibitor: The clinical data. Am J Orthop (Belle Mead NJ) 1999; 28: 13- 18.
26. Alfranca A, Lopez-Oliva JM, Genis L, et al. PGE2 induces angiogenesis via MT1-MMP-mediated activation of the TGFbeta/Alk5 signaling pathway. Blood 2008; 112: 1120- 1128.
27. Muhlethaler-Mottet A, Meier R, Flahaut M, et al. Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells. Mol Cancer 2008; 7: 55.
28. Ellis L, Pili R. Histone deacetylase inhibitors: Advancing therapeutic strategies in hematological and solid malignancies. Pharmaceuticals (Basel) 2010; 3: 2411- 2469.
29. Son DS, Wilson AJ, Parl AK, Khabele D. The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21. Cancer Biol Ther 2010; 9: 928- 935.